Clinical Trial Update: Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel for recurrent or persistent uterine cancer (uterine sarcoma) has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Sarcoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Sarcoma | Phase 2 | Status: TERMINATED